Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.47 |
| ▸ | MGLL | Q99685 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753087 | 0.92 | PTGS1 (0.45) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL13113726 | 0.89 | PTGS1 (0.55) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL12642012 | 0.86 | PTGS1 (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL15216717 | 0.86 | PTGS1 (0.46) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL10283084 | 0.86 | ALDH1A1 (0.59) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL15613431 | 0.84 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHHPGD | |
| SCHEMBL13881123 | 0.84 | PTGS1 (0.45) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL21767306 | 0.84 | PTGS1 (0.45) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL12107717 | 0.84 | PTGS1 (0.51) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL4011321 | 0.83 | PTGS1 (0.69) | PTGS1PTGS2MGLLFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140161806-A1 | IMMUNOGENIC SYNTHETIC GLYCOCONJUGATE FOR THE IMMUNOTHERAPY OF MELANOMA | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital) (IT) | 2014-06-12 | — | — | US | disclosed |
| US-8680043-B2 | Synthetic immunogenic glycoconjugate for melanoma immunotherapy | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (IT) | 2014-03-25 | — | — | US | disclosed |
| US-20120263735-A1 | SYNTHETIC IMMUNOGENIC GLYCOCONJUGATE FOR MELANOMA IMMUNOTHERAPY | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital) (IT) | 2012-10-18 | — | — | US | disclosed |
| US-20100280098-A1 | RECEPTOR TARGETED OLIGONUCLEOTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161806-A1 | IMMUNOGENIC SYNTHETIC GLYCOCONJUGATE FOR THE IMMUNOTHERAPY OF MELANOMA | CD47, CD4, CD14 | PTGS1 3040/4885PTGS2 3035/4885MGLL 323/4885 |
| US-20120263735-A1 | SYNTHETIC IMMUNOGENIC GLYCOCONJUGATE FOR MELANOMA IMMUNOTHERAPY | LGALS3, ST3GAL3, SIGLEC7 | PTGS1 1310/4885PTGS2 1497/4885MGLL 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.